Public Sector Pension Investment Board Has $2.94 Million Position in Artivion, Inc. $AORT

Key Points

• The Public Sector Pension Investment Board increased its stake in Artivion, Inc. by 27.4%, owning approximately $2.94 million worth of shares after acquiring an additional 25,698 shares.
• Artivion reported $0.24 EPS for the last quarter, surpassing analysts' expectations of $0.11, with a revenue of $112.97 million, representing a year-over-year increase of 15.3%.
• Recent analyst ratings show a consensus of "Buy" for Artivion, with target prices ranging from $40 to $45 set by multiple firms.

Public Sector Pension Investment Board increased its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 27.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 119,650 shares of the company's stock after purchasing an additional 25,698 shares during the period. Public Sector Pension Investment Board owned approximately 0.28% of Artivion worth $2,941,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of AORT. Peregrine Capital Management LLC acquired a new stake in shares of Artivion during the first quarter worth approximately $7,650,000. Point72 Asset Management L.P. acquired a new stake in shares of Artivion during the fourth quarter worth approximately $5,573,000. First Trust Advisors LP bought a new stake in shares of Artivion during the fourth quarter valued at approximately $4,771,000. Thornburg Investment Management Inc. bought a new stake in shares of Artivion during the first quarter valued at approximately $3,261,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Artivion during the first quarter valued at approximately $3,162,000. Institutional investors and hedge funds own 86.37% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AORT. Oppenheimer reissued an "outperform" rating on shares of Artivion in a research note on Friday, August 8th. Needham & Company LLC increased their price target on shares of Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Friday. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Wall Street Zen raised shares of Artivion from a "hold" rating to a "buy" rating in a research note on Monday. Finally, JMP Securities raised their price objective on shares of Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Artivion presently has an average rating of "Buy" and a consensus price target of $40.63.

Insider Activity at Artivion

In related news, SVP Marshall S. Stanton sold 15,000 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $29.50, for a total value of $442,500.00. Following the sale, the senior vice president directly owned 64,200 shares of the company's stock, valued at approximately $1,893,900. The trade was a 18.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 12,500 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares in the company, valued at $36,089,776.56. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 96,538 shares of company stock valued at $3,444,651. 8.10% of the stock is owned by insiders.

Artivion Trading Down 1.1%

Shares of NYSE AORT traded down $0.5050 during midday trading on Monday, reaching $44.3250. 68,283 shares of the stock were exchanged, compared to its average volume of 443,892. The business has a 50-day simple moving average of $33.65 and a two-hundred day simple moving average of $28.83. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -105.40 and a beta of 1.64. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.13. The company had revenue of $112.97 million for the quarter, compared to analysts' expectations of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. Artivion's quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.